Clinical trials: Proton Pump Inhibitors
Healthy
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations
- Trial name
- ERBA (NCT05446142)
- Testing
- Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Laryngopharyngeal Reflux
Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux
The purpose of this study is to determine whether Lansoprazole 30mg taken twice daily is effective in the treatment of laryngitis due to gastroesophageal reflux.
- Trial name
- NCT00369265
- Testing
- Lansoprazole, Sugar pill
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- American Institute for Voice and Ear Research
Gastro Oesophageal Reflux Disease
Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease
The goal of this clinical trial was to evaluate the effectiveness and safety of fexuprazan 40 mg for relieving symptoms of gastroesophageal reflux disease (GERD) in adults.
- Trial name
- NCT07326904
- Testing
- Fexuprazan, Esomeprazole
- Where
- 3 sites in Indonesia
- Volunteers
- 145 people
- Sponsor
- Universitas Indonesia
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms.
- Trial name
- NCT01404832
- Testing
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dallas VA Medical Center
Peptic Ulcer
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
- Trial name
- NCT01138969
- Testing
- esomeprazole
- Where
- Taiwan
- Volunteers
- 165 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Liver Cirrhosis, Hypertension, Portal
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
- Trial name
- PPIs (NCT03175731)
- Testing
- Proton Pump Inhibitors
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Yanjing Gao
Multiple Sclerosis
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the…
- Trial name
- NCT00938366
- Testing
- Cladribine, Pantoprazole
- Volunteers
- 18 people
- Sponsor
- Merck KGaA, Darmstadt, Germany